Mazdutide Achieves 20% Weight Loss in Phase 3 Obesity Trial, Innovent Plans China NDA Submission

Reuters11-20

Mazdutide Achieves 20% Weight Loss in Phase 3 Obesity Trial, Innovent Plans China NDA Submission

Innovent Biologics Inc. announced that its Phase 3 clinical trial of mazdutide, a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) met both its primary and all key secondary endpoints. Mazdutide 9 mg achieved up to 20.1% weight loss in obese adults without type 2 diabetes after one year of treatment using a 2-step dose titration. Innovent plans to submit a new drug application (NDA) for mazdutide 9 mg for weight management to the Center for Drug Evaluation $(CDE)$ of China's National Medical Products Administration (NMPA) in the near term. Clinical findings on mazdutide have already been published in international journals such as The New England Journal of Medicine, Nature Communications, Diabetes Care, and eClinicalMedicine, and have been presented at scientific conferences including those of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN28678) on November 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584726429?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584726429","market":"us","top_or_hot":-1,"title":"Mazdutide Achieves 20% Weight Loss in Phase 3 Obesity Trial, Innovent Plans China NDA Submission","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mazdutide Achieves 20% Weight Loss in Phase 3 Obesity Trial, Innovent Plans China NDA Submission\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> announced that its Phase 3 clinical trial of mazdutide, a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) met both its primary and all key secondary endpoints. Mazdutide 9 mg achieved up to 20.1% weight loss in obese adults without type 2 diabetes after one year of treatment using a 2-step dose titration. Innovent plans to submit a new drug application (NDA) for mazdutide 9 mg for weight management to the Center for Drug Evaluation <a href=\"https://laohu8.com/S/CDE\">$(CDE)$</a> of China's National Medical Products Administration (NMPA) in the near term. Clinical findings on mazdutide have already been published in international journals such as The <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine, Nature Communications, Diabetes Care, and eClinicalMedicine, and have been presented at scientific conferences including those of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN28678) on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mazdutide Achieves 20% Weight Loss in Phase 3 Obesity Trial, Innovent Plans China NDA Submission</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMazdutide Achieves 20% Weight Loss in Phase 3 Obesity Trial, Innovent Plans China NDA Submission\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 08:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mazdutide Achieves 20% Weight Loss in Phase 3 Obesity Trial, Innovent Plans China NDA Submission\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> announced that its Phase 3 clinical trial of mazdutide, a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) met both its primary and all key secondary endpoints. Mazdutide 9 mg achieved up to 20.1% weight loss in obese adults without type 2 diabetes after one year of treatment using a 2-step dose titration. Innovent plans to submit a new drug application (NDA) for mazdutide 9 mg for weight management to the Center for Drug Evaluation <a href=\"https://laohu8.com/S/CDE\">$(CDE)$</a> of China's National Medical Products Administration (NMPA) in the near term. Clinical findings on mazdutide have already been published in international journals such as The <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine, Nature Communications, Diabetes Care, and eClinicalMedicine, and have been presented at scientific conferences including those of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN28678) on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL7wxt6X:1","article_id":"2584726429","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584726429","pubTimestamp":1763596822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics Inc. announced that its Phase 3 clinical trial of mazdutide, a dual glucagon /glucagon-like peptide-1  receptor agonist, in Chinese adults with obesity  met both its primary and all key secondary endpoints. Mazdutide 9 mg achieved up to 20.1% weight loss in obese adults without type 2 diabetes after one year of treatment using a 2-step dose titration. Innovent plans to submit a new drug application  for mazdutide 9 mg for weight management to the Center for Drug Evaluation  of China's National Medical Products Administration  in the near term. Clinical findings on mazdutide have already been published in international journals such as The New England Journal of Medicine, Nature Communications, Diabetes Care, and eClinicalMedicine, and have been presented at scientific conferences including those of the American Diabetes Association  and the European Association for the Study of Diabetes .","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK1583":"高瓴概念","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1589":"北水核心资产","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","01911":"华兴资本控股","BK1147":"投资银行业与经纪业","BK1161":"生物科技","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","01801":"信达生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC"},"translate_title":"Mazdutide在3期肥胖试验中实现20%体重减轻，信达生物计划提交中国NDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01911":0.9,"01801":0.9},"content_text":"Mazdutide Achieves 20% Weight Loss in Phase 3 Obesity Trial, Innovent Plans China NDA Submission\n    \n\nInnovent Biologics Inc. announced that its Phase 3 clinical trial of mazdutide, a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) met both its primary and all key secondary endpoints. Mazdutide 9 mg achieved up to 20.1% weight loss in obese adults without type 2 diabetes after one year of treatment using a 2-step dose titration. Innovent plans to submit a new drug application (NDA) for mazdutide 9 mg for weight management to the Center for Drug Evaluation $(CDE)$ of China's National Medical Products Administration (NMPA) in the near term. Clinical findings on mazdutide have already been published in international journals such as The New England Journal of Medicine, Nature Communications, Diabetes Care, and eClinicalMedicine, and have been presented at scientific conferences including those of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN28678) on November 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584726429","isCrawlerRequest":true}